JUSTIN WOODRUFF: Open Payments
NPI 1063020949 · BRIGHAM CITY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,352 in 64 payments from 9 companies in 2025. Trend: 2023 $14,163 · 2024 $10,270 · 2025 $4,352
Speaker / faculty: $3,375Food & beverage: $977
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $3,454 |
| Otsuka America Pharmaceutical, Inc. | 17 | $203 |
| Alkermes, Inc. | 14 | $202 |
| Neurocrine BioSciences, Inc. | 9 | $187 |
| Vanda Pharmaceuticals Inc. | 5 | $154 |
| Teva Pharmaceuticals USA, Inc. | 6 | $92 |
| Tris Pharma Inc | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
Products named: VRAYLAR, INGREZZA, FANAPT, ABILIFY ASIMTUFII, LYBALVI, ARISTADA, REXULTI, AUSTEDO XR.
Industry payments across UT — which companies pay providers there.
